Boxes

0.1.1	Key challenges for the future in financing health systems for UHC	*page* li
0.2.1	What is UHC?	1
0.2.2	Defining efficiency, equity and quality in health care and systems	3
1.1.1	Parallel tax and SHI systems: India	36
1.1.2	Strengthening the tax system: Georgia	46
1.3.1	Medical savings accounts are inefficient, inequitable and do not provide sufficient financial protection	93
1.3.2	France demonstrates how difficult it is to achieve high levels of population coverage for complementary VHI covering user charges	107
1.3.3	VHI distorts the use of health system resources	108
2.1.1	Retrospective risk adjustment	150
2.2.1	Benefits of setting an explicit benefits package	169
2.5.1	Personal budgets in the Netherlands	257
3.1.1	The role of information technology and digital health infrastructure for primary care payment models	292
3.1.2	Payment methods for community pharmacists as their role expands to a first-contact point with the health system	296
3.1.3	Case study: the Quality and Outcomes Framework (QOF)	300
3.3.1	Adverse effects of informal payments on health systems	364
3.4.1	Definition: intellectual property rights	409
3.4.2	The role of public funding: COVID-19 vaccines and therapeutics	411
3.4.3	Industry spending on lobbying, marketing and consolidation	413

Published online by Cambridge University Press

3.4.4	How do push and pull mechanisms work? Examples in the area of antimicrobial resistance (AMR)	414
3.4.5	Addressing R&D shortages: repurposing of medicines	418
3.4.6	What shapes manufacturers' prices?	428
3.4.7	Zolgensma® – worth the high price tag?	429
3.5.1	Common payment mechanisms in health care systems	455
3.6.1	Fragmentation within LTC financing systems	486
3.6.2	Summary of potential market failures in LTC and possible policy tools to mitigate them	489
3.6.3	Day care	496
3.6.4	Other tools to incentivize quality of LTC	499
3.7.1	Thailand's UHC scheme	525
3.7.2	Ghana's National Health Insurance Scheme	526
3.8.1	One Health approach	542
3.8.2	Programme budgeting: Australia	556
3.8.3	Pandemic Emergency Finance Facility (PEF)	561
3.10.1	PDP case study: Medicines for Malaria Venture and Coartem	635

Published online by Cambridge University Press